Introduction: Psoriasis is a chronic inflammatory skin disease significantly impairing quality of life. The introduction of biologic therapies, such as bimekizumab—a monoclonal antibody targeting IL-17A and IL-17F—has revolutionized treatment outcomes. This study investigates the effectiveness of bimekizumab in a real-world setting, focusing on the predictors of Early Super Response (ESR), defined as achieving PASI 100 by week 4, and evaluates the safety profile over a 48-week follow-up period. Methods: A retrospective study was conducted on 109 psoriasis patients treated with bimekizumab at two Italian dermatology centers. Of these, 61 patients completed a 48-weeks follow-up. Baseline clinical and demographic data, PASI scores at multiple time points, and adverse events were collected. ESR predictors were analyzed using univariate and multivariate logistic regression models. Safety was assessed using Cox proportional hazards models to find predictive factors associated with the risk of adverse events (AEs). Results: At week 4, 28.4% of patients achieved PASI 100. Baseline PASI (OR: 0.93, p = 0.029), absence of nail involvement (OR: 0.12, p = 0.003), and fewer biologic failures (OR: 0.14, p = 0.038) were independently associated with ESR status. Safety analysis revealed that 15.6% of patients experienced adverse events, with asthma/allergic rhinitis significantly associated with a higher risk (HR: 6.43, p = 0.012). Candidiasis (7.3%) and eczema (4.6%) were the most common adverse events. Conclusion: Bimekizumab demonstrated significant effectiveness and an acceptable safety profile in a real-world setting. Baseline PASI, nail involvement, and prior biologic failures influenced early treatment response. Identifying predictors of ESR and adverse events can guide personalized therapeutic approaches, optimizing outcomes for psoriasis patients.

Purpose: This prospective, single-center, open-label study aimed to evaluate the efficacy and safety of 1470 nm non-ablative laser therapy in treating facial acne scars. The primary objective was to assess improvements in skin texture, elasticity, and scar depth and diameter, while confirming the absence of significant adverse effects. Patients and Methods: 40 healthy female volunteers aged 18 to 42 years with facial acne scars underwent three sessions of 1470 nm laser therapy at two-week intervals. Outcome measures included cutometric assessments, high-frequency ultrasound evaluations, and clinical photographic documentation, conducted at baseline and on days 21, 42, 70, and 130 post-treatment. Results: Significant improvements were observed across all evaluated parameters. Skin elasticity increased progressively from baseline (mean: 62.95, SD=4.0) to day 21 (63.72, SD=3.8, +4%), day 42 (67.11, SD=4.0, +6%), day 70 (69.08, SD=4.2, +11%), and day 130 (70.80, SD=4.4, +14%; p< 0.001). High-frequency ultrasound measurements revealed substantial reductions in scar depth, which decreased by 5% at day 21 (mean: 0.18 mm, SD=0.05, p< 0.001), 20% at day 42 (0.15 mm, SD=0.055, p< 0.001), 48% at day 70 (0.10 mm, SD=0.06, p< 0.001), and 63% at day 130 (0.07 mm, SD=0.065, p< 0.001). Scar diameter followed a similar trend, with reductions of 16% at day 21 (3.08 mm, SD=0.3, p< 0.001), 26% at day 42 (2.71 mm, SD=0.34, p< 0.001), 42% at day 70 (2.13 mm, SD=0.36, p< 0.001), and 62% at day 130 (1.39 mm, SD=0.38, p< 0.001). Clinical photographic evaluations corroborated these quantitative findings, showing visible improvements in scar appearance and overall skin texture. No adverse events were reported throughout the study. Conclusion: The 1470 nm non-ablative laser therapy demonstrated high efficacy and safety in the treatment of acne scars, delivering substantial therapeutic benefits and high patient satisfaction, offering a valuable therapeutic option for addressing both pigmentation and textural issues associated with acne scars.

Objectives: This study aimed to evaluate the prevalence of lichen sclerosus (LS) in male patients undergoing circumcision for phimosis, emphasising the significance of a multidisciplinary approach in the early diagnosis and management of this condition. Methods: A retrospective analysis was performed on 841 male patients who underwent circumcision at a high‐volume medical centre between 2001 and 2023. Data were collected on clinical diagnoses made by both dermatologists and urologists, along with the corresponding histological findings. Logistic regression models were utilised to assess diagnostic accuracy and the relationship between clinical suspicion and histological confirmation. Results: Histological confirmation of LS was identified in 30.6% of the cases. Dermatologists demonstrated a diagnostic accuracy of 81.8%, whereas urologists showed an accuracy of 46.1%. The evaluations conducted by dermatologists exhibited a significant correlation with histological confirmation of LS (odds ratio 4.81; 95% confidence interval: 1.96–11.80; p = 0.001). Conclusions: This study elucidates the differences in diagnostic accuracy between dermatologists and urologists in identifying LS in patients undergoing circumcision for phimosis, highlighting the necessity of a multidisciplinary approach to improve the diagnostic process. Furthermore, the epidemiological data obtained from this research offer valuable insights into the prevalence of LS and the associated diagnostic challenges within a substantial patient cohort.

Generalised Granuloma Annulare (GGA) is a chronic inflammatory skin disorder with no standard treatment. Since the last review in 2013, new treatments and varied responses have highlighted the need for an updated synthesis to guide clinical decisions. This systematic review aimed to evaluate the epidemiology, comorbidities and treatment outcomes in patients with GGA, synthesising evidence from published studies to provide insights into both conventional and emerging therapeutic strategies. A systematic literature search was conducted in CENTRAL, Embase and PubMed, following PRISMA guidelines. Studies published in English, French or Spanish up to January 15, 2024, were included. Data extraction focused on patient demographics, comorbidities, treatment regimens and therapeutic outcomes. A total of 689 patients were included. The mean age of patients was 52.8 years, with a female predominance (72.6%). Based on this systematic review, we propose a stepwise approach: first‐line treatment includes hydroxychloroquine and phototherapy (PUVA > UVA1 > nb‐UVB). Oral corticosteroids along with high‐potency topical steroids or calcineurin inhibitors may be used in extensive or rapidly progressive disease or as bridging therapy pending slower‐acting agents. Sulfones are second‐line, with oral retinoids (e.g., isotretinoin) as alternatives if contraindicated. For refractory cases, off‐label anti‐TNF‐α agents or JAK inhibitors are recommended, with methotrexate or cyclosporine as valid alternatives. This largest systematic review of GGA treatments offers an evidence‐based clinical framework. While steroids and phototherapy remain standard, emerging options like JAK inhibitors and biologics show promise for refractory cases. Tailored, multimodal strategies may improve outcomes, though further trials are needed to standardise guidelines.